40 results about "Busulfan" patented technology

The invention discloses a busulfan composition and a preparation method and an application thereof. The busulfan composition comprises the following substances in a weight ratio: a proportion of busulfan to cyclodextrin is 1-20:100-2000. The busulfan composition is preferably prepared by the following method: dissolving the busulfan by using an organic solvent, and preparing the busulfan solutionof which the concentration is 1-20 mg / mL; dissolving SBE-Beta-cyclodextrin by using water for injection, preparing 10-40% (w / v) of SBE-Beta-cyclodextrin water solution; in a nitrogen atmosphere, mixing two types of the solution, after stirring for 1 hour, and removing the organic solvent; and filtering, and freeze-drying. The busulfan composition can be used for a tablet and injection. It is proved from research that the busulfan composition is capable of remarkably improving stability of the busulfan. The busulfan composition is lower in injection irritation, can be used for clinic injection,and is capable of improving safety of drug use as well as guaranteeing product stability.

Novel conjugates of busulfan and novel busulfan immunogens derived from α-substituted derivatives of busulfan and antibodies generated by these busulfan linked immunogens are useful in immunoassays for the quantification and monitoring of busulfan in biological fluids.

New uses for phenylketone carboxylate compounds and substituted aromatic compounds of Formula I, Formula I.1, Formula I.2, Formula IA, Formula IB, Formula IC and Formula II and their pharmaceutical acceptable salts for the treatment of cancer. The use of a combination of two of these compounds is described and the use of the combination of one of these compounds with an anticancer agent such as decarbazine, doxorubicin, daunorubicin, cyclophosphamide, busulfex, busulfan, vinblastine, vincristine, bleomycin, etoposide, topotecan, irinotecan, taxotere, taxol, 5-fluorouracil, methotrexate, gemcitabine, cisplatin, carboplatin and chlorambucil.

The invention discloses a method for building a mouse severe aplastic anemia model, wherein the mouse severe aplastic anemia model is built through combination of an interferon-gama with a busulfan administration method, and the mouse severe aplastic anemia model induced by the invention is simple and convenient in method and high in success rate of induction and accords with the characteristics of human aplastic anemia.

The invention discloses a combined chemotherapeutic agent for transplantation pretreatment of thalassemia stem cells in children, which comprises the following components: 5 mg / m<2>*5 days of cladrobin, 1.8 g / m<2>*2 days of cyclophosphamide, 4-4.8 mg / kg*3 days of busulfan and 2.5 mg / kg*2 days of anti-human thymus globulin. The combined chemotherapeutic agent is based on the cladrobin, and the cladrobin is combined with the cyclophosphamide, the busulfan and anti-human thymus globulin to perform pre-treatment large-dose chemotherapy before transplantation of Mediterranean stem cells of children, so that the compliance and tolerance of the chemotherapy are improved, the immunosuppression strength is increased, the transplantation success rate of transplantation of stem cells of a patient isimproved, the transplantation-related complications are reduced, the transplantation curative effect is improved, the survival time of the patient is prolonged, and the combined chemotherapeutic agenthas good social benefit and economic benefit and wide clinical application prospect. The efficient and safe pretreatment scheme can be used for transplantation of thalassemia stem cells in children,and the transplantation survival rate is improved.

Compositions and methods for selectively and permanently removing hair from the body. The compositions are formulated to be topically applied upon discrete areas of the body and contain an agent present in an amount sufficient to cause permanent alopecia about the area upon which the composition is applied. Exemplary of such agents include taxanes, such as docetaxel and paclitaxel, and busulfan and other agents known in the art to cause permanent chemotherapy-induced alopecia (CIA). The compositions and methods of applying the same are limited exclusively to transdermal application and operative to induce a localized CIA, and thus avoid systemic distribution of the CIA agent throughout the body. The compositions may further be deployed through known transdermal application mechanisms, such as transdermal patches and the like.

The invention belongs to the field of biochemical pharmacy and provides application of a swim bladder polypeptide to medicines for inhibiting oxidative damage and cell apoptosis in human bodies or animal bodies. The oxidative damage refer to testicle oxidative damage, the cell apoptosis refers to testicular spermatogenic cell apoptosis, the oxidative damage and the cell apoptosis are caused by antitumor drugs including busulfan, cyclophosphamide and thiotepa, and busulfan is used as the antitumor drug in an embodiment. The swim bladder polypeptide is capable of raising the expression level ofa transcription factor Nrf2, reducing an apoptosis promoting factor Bax and raising the expression level of an anti-apoptosis factor Bcl2; the swim bladder polypeptide is capable of relieving busulfaninduced germ cell vacuolization, spermatogenic cell apoptosis, seminiferous tubule degradation and sperm amount and viability reduction. By adoption of the swim bladder polypeptide for preparation ofthe medicines for inhibiting oxidative damage and cell apoptosis, medicines for recovering fertility of men or male animals can be prepared, and a direction is provided for treatment of fertility ofmen or male animals.

The invention discloses a novel application of Omega-3 or pharmaceutically acceptable fatty acid thereof, and the novel application comprises an application of Omega-3 or pharmaceutically acceptable fatty acid thereof in preparation of a medicine for treating NOA. Through eicosanoic acid targeted metabonomics, it is screened that DHA and EPA in testicular tissue of a polyunsaturated fatty acid Omega-3 gavage male mouse are obviously up-regulated. Experiments prove that Omega-3 is injected into the stomach of a busulfan-induced NOA mouse, the thickness and integrity of testis recovery spermatogenic epithelium and the concentration of epididymis tail sperms can be observed, and meanwhile, proliferation and differentiation of spermatogonium and expression of supporting cell paracrine factors are promoted, so that the Omega-3 can be used as a new target for improving the NOA mouse testis spermatogenic dysfunction; a novel method is provided for treating the non-obstructive azoospermia.

Use of busulfan amide as stabilized standards in immunoassays for quantifying the amount of busulfan in samples of human biological fluids, methods for carrying out said immunoassay and kits for use in said immunoassay.